Stock Events

Stock Events

Cellectar Biosciences 

€0
54
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-4.38
-2.73
-1.09
0.56
Expected EPS
-1.6359915
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-84.09MNet Income

Analyst Ratings

$7.59Average Price Target
The highest estimate is 7.59.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NV40.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Adc Therapeutics SA
ADCT
Mkt Cap501.75M
ADC Therapeutics focuses on developing antibody-drug conjugates for cancer treatment, directly competing with Cellectar's cancer-targeting therapies.
Allogene Therapeutics
ALLO
Mkt Cap275.13M
Allogene Therapeutics works on allogeneic CAR T cell therapies, a different but competing approach in the broader cancer treatment landscape against Cellectar's offerings.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the oncology space, particularly in cell therapies that could be alternatives to Cellectar's treatments.
Novartis
NVS
Mkt Cap237.61B
Novartis offers a broad range of oncology treatments, including targeted therapies and cell therapy products that compete with Cellectar's cancer treatments.
AMGEN
AMGN
Mkt Cap160.66B
Amgen's extensive portfolio in oncology, including biosimilars and novel therapeutics, positions it as a competitor across various aspects of cancer treatment, challenging Cellectar's market.

About

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
Show more...
CEO
ISIN
US15117F8804
WKN
000A41BQ3

Listings

F
DE
NV40.F
XNAS
US
CLRB
BOATS
BOATS
CLRB.BOATS

0 Comments

Share your thoughts

FAQ

What is Cellectar Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cellectar Biosciences stocks are traded under the ticker NV40.F.
Is Cellectar Biosciences stock price growing?▼
NV40.F stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Cellectar Biosciences has showed a +9.35% increase.
When is the next Cellectar Biosciences earnings date?▼
Cellectar Biosciences is going to release the next earnings report on May 12, 2026.
What were Cellectar Biosciences earnings last quarter?▼
NV40.F earnings for the last quarter are 0.56 EUR per share, whereas the estimation was -1.05 EUR resulting in a +153.07% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Cellectar Biosciences revenue for the last year?▼
Cellectar Biosciences revenue for the last year amounts to 0 EUR.
What is Cellectar Biosciences net income for the last year?▼
NV40.F net income for the last year is -84.09M EUR.
When did Cellectar Biosciences complete a stock split?▼
The last stock split for Cellectar Biosciences was on June 24, 2025 with a ratio of 1:30.